+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are studying the effectiveness of a tetravalent dengue vaccine TDV in reducing hospital stays due to dengue in children and adolescents aged 6 to 12 years living in Southeast Asian countries with high dengue transmission, including Thailand, Indonesia, and Malaysia. This observational study focuses on participants in a community-based cohort who may or may not receive the vaccine as part of a pilot public vaccination program where TDV is already approved. The study particularly aims to assess the vaccines effectiveness against less common dengue virus types DENV-3 and DENV-4. The study includes a nested case-control design with two groups cases who are hospitalized children or adolescents with confirmed dengue infection, and matched controls who live in the same neighborhood but have not been hospitalized with dengue. Participants are followed individually for up to 3 years within the cohort. The study is non-interventional, observing outcomes based on vaccination status within the existing vaccination program. Participants will be monitored through active hospital surveillance to identify dengue hospitalizations confirmed by laboratory testing. Data collected includes blood samples for RT-PCR testing, clinical diagnosis, and hospitalization records. Researchers will measure the rate of hospitalization due to dengue virus infections by serotype and baseline dengue immune status. The primary outcome is dengue-related hospitalization up to 36 months. Parents or legal representatives provide consent and assent for participants, including agreement for blood sample collection and follow-up over the study period.

Age: 6Years - 12YearsAll Genders
7 locations
S

Actively Recruiting

Atrial fibrillation AF is a major cause of heart-related illness and death, especially among Asian patients who face higher risks of serious bleeding such as brain hemorrhage compared to non-Asians. This research, called the COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation COOL-AF Phase 2, aims to study how antithrombotic medication use changes over time and how these changes affect health outcomes in people with AF. The study is observational and conducted across multiple centers in Thailand. Participants in this study have known or newly diagnosed non-valvular AF and are followed without any intervention or treatment assigned by the study. The study plans to enroll about 3680 patients over two years from 33 centers. Participants will be monitored every 6 months for up to 3 years to observe patterns of medication use, particularly warfarin and non-vitamin K antagonist oral anticoagulants NOACs, and clinical events including stroke, systemic embolism, bleeding, heart attacks, and heart failure. Throughout the study, patients will have regular check-ins every six months to track their medication usage and health status. Researchers will collect data on important outcomes such as rates of stroke, bleeding events, and quality of life. The studys primary focus is on long-term safety and effectiveness of antithrombotic treatments in this population. The total participation duration can be up to 3 years, ensuring thorough observation of clinical outcomes and treatment patterns.

Age: 18Years - 100YearsAll Genders
33 locations
E

Actively Recruiting

This study focuses on adults undergoing coronary angiography and left heart catheterization to evaluate the accuracy of using the common femoral vein-to-artery diameter ratio as a diagnostic tool for detecting elevated left ventricular end-diastolic pressure LVEDP. Elevated LVEDP is an indicator of volume overload and is measured during left heart catheterization, which serves as the reference standard in this prospective cross-sectional diagnostic accuracy study. Participants undergo ultrasound measurements of the diameters of the common femoral vein and artery while lying in the supine position. These measurements are used to calculate the vein-to-artery diameter ratio, which is assessed as a potential non-invasive diagnostic index for elevated LVEDP. No therapeutic interventions are administered during the study. Throughout the study, participants receive ultrasound examinations and left heart catheterization as part of their clinical care. Researchers collect measurements during these procedures to evaluate the diagnostic performance of the ultrasound ratio. The main outcome measured is the left ventricular end-diastolic pressure during cardiac catheterization. The study is observational, with no additional treatments provided, and is expected to complete by the end of 2026.

Age: 18Years - 100YearsAll Genders
1 location
C

Actively Recruiting

Researchers are comparing two methods of minimal invasive surgery to treat severe Hallux Valgus, a condition affecting the big toe causing pain and deformity. This randomized controlled trial evaluates the outcomes of using either one or two Kirshner wires for fixation during distal linear metatarsal osteotomy. The study aims to understand if adding a second wire improves stability, reduces complications like recurrence and infections, and enhances pain relief and function. Participants are divided into two groups of 25 each. One group receives the standard fixation with one Kirshner wire placed through the first metatarsal bone, while the other group has an additional wire inserted across the metatarsophalangeal joint for extra stability. This second-generation minimal invasive surgery is chosen for its cost-effectiveness, less pain, smaller scars, shorter surgery time, and reduced blood loss. Over a follow-up period of one year, participants will attend regular visits to complete questionnaires and undergo radiographic exams to measure the Hallux Valgus Angle at baseline and multiple time points up to 12 months. Researchers will analyze pain, function, and complications to compare the two fixation methods. The study involves detailed monitoring to assess the effectiveness and safety of the surgical techniques.

Age: 18Years - 60YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.

Age: 18Years - 75YearsAll GendersPhase 2
223 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the epidemiological impact and cost-effectiveness of long-acting antiretrovirals for HIV prevention among Thai men who have sex with men MSM and transgender women TGW. The study includes discrete choice experiments DCEs to understand preferences for different pre-exposure prophylaxis PrEP options, as well as analysis of routine service data. The findings will guide mathematical modeling of long-acting PrEP uptake and its impact on HIV prevention. The study has three phases. Phase I involves in-depth interviews IDIs and focus group discussions FGDs with current, previous, or interested PrEP users to identify important attributes for PrEP choices. Phase II pilots the DCEs with convenience samples to refine the survey. Phase III launches two final surveys for MSM and TGW, collecting data on demographics, risk behavior, HIV and STI testing, PrEP knowledge, use, and preferences across attributes like product form, dosing frequency, provider type, and cost. Participants will take part in interviews, group discussions, and surveys conducted either in person or online. Data collected includes sociodemographic information, risk behaviors, PrEP attitudes, and preferences. Researchers will measure the projected uptake of long-acting PrEP, epidemiological impact, and cost-effectiveness over 12 to 18 months. The study includes ongoing monitoring of participant responses to optimize understanding of factors influencing PrEP use.

Age: 18Years +MALEPhase Not Applicable
12 locations
P

Actively Recruiting

Researchers are evaluating whether peripheral magnetic stimulation PMS during balance training can reduce the risk of falls and lessen disease severity in patients with diabetic polyneuropathy. This proof-of-concept Phase 2 trial uses the Magnetic and Balance Training Activator MAGBATA platform, which delivers electromagnetic pulses directly to the soles of the feet while standing. The study focuses on improving sensory input, brain plasticity, and nerve regeneration in affected patients. Participants will be randomly assigned to either an active intervention group or a control group. The active group receives a warm-up exercise with ankle dorsiflexion combined with 10 Hz repetitive peripheral magnetic stimulation rPMS to the tibialis anterior of each leg, followed by one-leg stance exercises on the MAGBATA platform with 20 Hz rPMS applied to the foot sole. The control group performs the same exercises but with sham stimulation. Each participant undergoes 8 sessions over 4 weeks, with two sessions per week. During the study, participants will be assessed using balance tests including the one-leg stance test, timed up and go test, and short physical performance battery at baseline and after the intervention. Electrophysiologic nerve conduction studies will be performed at baseline and at week 8 to evaluate disease severity. Safety measures include supervised exercises with fall prevention devices. Total participation lasts at least 8 weeks, including follow-up assessments.

Age: 50Years - 75YearsAll GendersPhase 2
1 location
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.

Age: 18Years - 100YearsAll Genders
49 locations